{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Algie post-zona : Questions médicales les plus fréquentes",
"headline": "Algie post-zona : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Algie post-zona : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-13",
"dateModified": "2025-04-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Algie post-zona"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Névralgie",
"url": "https://questionsmedicales.fr/mesh/D009437",
"about": {
"@type": "MedicalCondition",
"name": "Névralgie",
"code": {
"@type": "MedicalCode",
"code": "D009437",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.888.592.612.664"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Algie post-zona",
"alternateName": "Neuralgia, Postherpetic",
"code": {
"@type": "MedicalCode",
"code": "D051474",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Song Cao",
"url": "https://questionsmedicales.fr/author/Song%20Cao",
"affiliation": {
"@type": "Organization",
"name": "Department of Pain Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China."
}
},
{
"@type": "Person",
"name": "Dexin Zhang",
"url": "https://questionsmedicales.fr/author/Dexin%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Pain Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China."
}
},
{
"@type": "Person",
"name": "Jie Yuan",
"url": "https://questionsmedicales.fr/author/Jie%20Yuan",
"affiliation": {
"@type": "Organization",
"name": "Department of Pain Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China."
}
},
{
"@type": "Person",
"name": "Ying Li",
"url": "https://questionsmedicales.fr/author/Ying%20Li",
"affiliation": {
"@type": "Organization",
"name": "Department of Pain Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China."
}
},
{
"@type": "Person",
"name": "Yuanyuan Ding",
"url": "https://questionsmedicales.fr/author/Yuanyuan%20Ding",
"affiliation": {
"@type": "Organization",
"name": "Department of Pain Management, Shengjing Hospital of China Medical University, Shenyang, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized scleroderma Total Severity Scale (LoTSS).",
"datePublished": "2023-12-26",
"url": "https://questionsmedicales.fr/article/38148547",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/acr.25281"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Collaborative National Quality and Efficacy Registry for Scleroderma: association of medication use on gastrointestinal tract symptoms in early disease and the importance of tobacco cessation.",
"datePublished": "2023-07-25",
"url": "https://questionsmedicales.fr/article/37497718",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.55563/clinexprheumatol/04rauu"
}
},
{
"@type": "ScholarlyArticle",
"name": "False positive anti-Topoisomerase I (Scl-70) antibody results in clinical practice: A case series from a scleroderma referral center.",
"datePublished": "2022-06-17",
"url": "https://questionsmedicales.fr/article/35753143",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.semarthrit.2022.152052"
}
},
{
"@type": "ScholarlyArticle",
"name": "Measurement equivalence of the English and French versions of the self-efficacy to manage chronic disease scale: a Scleroderma Patient-Centered Intervention Network (SPIN) study.",
"datePublished": "2024-01-09",
"url": "https://questionsmedicales.fr/article/38191792",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11136-023-03571-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hyaluronic Acid Filler Injection for Localized Scleroderma - Case Report and Review of Literature on Filler Injections for Localized Scleroderma.",
"datePublished": "2022-08-11",
"url": "https://questionsmedicales.fr/article/35983128",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2147/CCID.S356641"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "États, signes et symptômes pathologiques",
"item": "https://questionsmedicales.fr/mesh/D013568"
},
{
"@type": "ListItem",
"position": 3,
"name": "Signes et symptômes",
"item": "https://questionsmedicales.fr/mesh/D012816"
},
{
"@type": "ListItem",
"position": 4,
"name": "Manifestations neurologiques",
"item": "https://questionsmedicales.fr/mesh/D009461"
},
{
"@type": "ListItem",
"position": 5,
"name": "Névralgie",
"item": "https://questionsmedicales.fr/mesh/D009437"
},
{
"@type": "ListItem",
"position": 6,
"name": "Algie post-zona",
"item": "https://questionsmedicales.fr/mesh/D051474"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Algie post-zona - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Algie post-zona",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Algie post-zona",
"description": "Comment diagnostique-t-on l'algie post-zona ?\nQuels examens peuvent être réalisés ?\nQuels symptômes indiquent une algie post-zona ?\nPeut-on confondre l'algie post-zona avec d'autres douleurs ?\nQuel rôle joue l'historique médical dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D051474?mesh_terms=Scleroderma,+Localized&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Algie post-zona",
"description": "Quels sont les symptômes principaux de l'algie post-zona ?\nLa douleur est-elle constante ou intermittente ?\nY a-t-il des symptômes associés ?\nComment la douleur est-elle décrite par les patients ?\nLes symptômes varient-ils d'une personne à l'autre ?",
"url": "https://questionsmedicales.fr/mesh/D051474?mesh_terms=Scleroderma,+Localized&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Algie post-zona",
"description": "Peut-on prévenir l'algie post-zona ?\nQui devrait se faire vacciner contre le zona ?\nY a-t-il des mesures à prendre après une éruption de zona ?\nLa gestion du stress aide-t-elle à prévenir l'algie ?\nLes soins de la peau sont-ils importants après le zona ?",
"url": "https://questionsmedicales.fr/mesh/D051474?mesh_terms=Scleroderma,+Localized&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Algie post-zona",
"description": "Quels traitements sont efficaces contre l'algie post-zona ?\nLes médicaments topiques sont-ils utiles ?\nLa physiothérapie peut-elle aider ?\nY a-t-il des traitements non médicamenteux ?\nLes traitements sont-ils toujours efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D051474?mesh_terms=Scleroderma,+Localized&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Algie post-zona",
"description": "Quelles sont les complications possibles de l'algie post-zona ?\nL'algie post-zona peut-elle affecter la qualité de vie ?\nY a-t-il un risque de dépression avec l'algie post-zona ?\nLes douleurs peuvent-elles s'aggraver avec le temps ?\nDes infections peuvent-elles survenir après le zona ?",
"url": "https://questionsmedicales.fr/mesh/D051474?mesh_terms=Scleroderma,+Localized&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Algie post-zona",
"description": "Quels sont les facteurs de risque de l'algie post-zona ?\nLe stress est-il un facteur de risque ?\nLes personnes atteintes de maladies chroniques sont-elles à risque ?\nLes femmes sont-elles plus à risque que les hommes ?\nL'immunosuppression augmente-t-elle le risque ?",
"url": "https://questionsmedicales.fr/mesh/D051474?mesh_terms=Scleroderma,+Localized&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on l'algie post-zona ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique médical et l'examen physique, sans tests spécifiques."
}
},
{
"@type": "Question",
"name": "Quels examens peuvent être réalisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens d'imagerie comme l'IRM peuvent être utilisés pour exclure d'autres causes de douleur."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une algie post-zona ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une douleur intense, brûlante ou lancinante dans la zone de l'éruption cutanée est typique."
}
},
{
"@type": "Question",
"name": "Peut-on confondre l'algie post-zona avec d'autres douleurs ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec d'autres douleurs neuropathiques ou musculo-squelettiques."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'historique médical dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'historique d'une infection par le virus varicelle-zona est crucial pour le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux de l'algie post-zona ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur intense, hypersensibilité et parfois démangeaisons."
}
},
{
"@type": "Question",
"name": "La douleur est-elle constante ou intermittente ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "La douleur peut être constante ou survenir par épisodes, souvent aggravée par le toucher."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, l'anxiété et des troubles du sommeil peuvent être présents."
}
},
{
"@type": "Question",
"name": "Comment la douleur est-elle décrite par les patients ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients décrivent souvent la douleur comme brûlante, lancinante ou en coup de poignard."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'une personne à l'autre ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la durée des symptômes peuvent varier considérablement entre les individus."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'algie post-zona ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination contre le zona peut réduire le risque de développer l'algie post-zona."
}
},
{
"@type": "Question",
"name": "Qui devrait se faire vacciner contre le zona ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les adultes de 50 ans et plus sont recommandés pour recevoir le vaccin contre le zona."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures à prendre après une éruption de zona ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est conseillé de consulter un médecin rapidement après une éruption pour un traitement précoce."
}
},
{
"@type": "Question",
"name": "La gestion du stress aide-t-elle à prévenir l'algie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la gestion du stress peut aider à réduire le risque de douleurs chroniques après le zona."
}
},
{
"@type": "Question",
"name": "Les soins de la peau sont-ils importants après le zona ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, maintenir la peau propre et hydratée peut aider à prévenir les complications cutanées."
}
},
{
"@type": "Question",
"name": "Quels traitements sont efficaces contre l'algie post-zona ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des analgésiques, des anticonvulsivants et des antidépresseurs."
}
},
{
"@type": "Question",
"name": "Les médicaments topiques sont-ils utiles ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des crèmes anesthésiques peuvent soulager la douleur localement dans certains cas."
}
},
{
"@type": "Question",
"name": "La physiothérapie peut-elle aider ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La physiothérapie peut aider à gérer la douleur et améliorer la fonction dans certains cas."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non médicamenteux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques comme la thérapie cognitivo-comportementale peuvent être bénéfiques."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils toujours efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité des traitements varie, et certains patients peuvent ne pas répondre aux thérapies."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de l'algie post-zona ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des douleurs chroniques, des troubles du sommeil et de l'anxiété."
}
},
{
"@type": "Question",
"name": "L'algie post-zona peut-elle affecter la qualité de vie ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la douleur chronique peut significativement impacter la qualité de vie et le bien-être."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque de dépression avec l'algie post-zona ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la douleur chronique peut augmenter le risque de dépression chez les patients."
}
},
{
"@type": "Question",
"name": "Les douleurs peuvent-elles s'aggraver avec le temps ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans certains cas, la douleur peut devenir plus intense et persistante avec le temps."
}
},
{
"@type": "Question",
"name": "Des infections peuvent-elles survenir après le zona ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections cutanées peuvent survenir si la peau est lésée pendant l'éruption."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de l'algie post-zona ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge avancé, un système immunitaire affaibli et des antécédents de zona."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut affaiblir le système immunitaire et augmenter le risque d'algie post-zona."
}
},
{
"@type": "Question",
"name": "Les personnes atteintes de maladies chroniques sont-elles à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies chroniques peuvent augmenter le risque de développer l'algie post-zona."
}
},
{
"@type": "Question",
"name": "Les femmes sont-elles plus à risque que les hommes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent que les femmes peuvent être légèrement plus à risque que les hommes."
}
},
{
"@type": "Question",
"name": "L'immunosuppression augmente-t-elle le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunosupprimées ont un risque accru de développer l'algie post-zona."
}
}
]
}
]
}
Juvenile localized scleroderma (jLS) is a chronic autoimmune disease commonly associated with poor outcome, including contractures, hemi-atrophy, uveitis, and seizures. Despite improvements in treatme...
LoTSS was developed as a weighted measure by a consensus process involving literature review, surveys, case vignettes, and multi-criteria decision analysis. Feasibility was assessed in larger Childhoo...
LoTSS severity items were organized into modules that reflect jLS disease patterns, with modules for skin, extracutaneous, and craniofacial manifestations. Construct validity of LoTSS was supported by...
We developed a new LS measure for assessing cutaneous and extracutaneous severity, and have shown it to be reliable, valid, and responsive. LoTSS is the first measure that assesses and scores all the ...
Systemic Sclerosis (SSc) is frequently associated with gastrointestinal tract (GIT) involvement. The Collaborative National Quality and Efficacy Registry (CONQUER) is a US-based collaborative study co...
CONQUER participants that had completed a minimum of two serial Scleroderma Clinical Trials Consortium GIT Questionnaires (GIT 2.0) were included in this analysis. Patients were categorised by total G...
415 enrolled CONQUER participants met project inclusion criteria. Most participants had stable mild GIT symptoms at baseline and were on immunomodulatory and anti-reflux therapy. In most patients, ant...
This report from the CONQUER cohort, suggests that most patients with early SSc have stable and mild GIT disease. Closer follow-up was associated with milder, stable GIT symptoms. There was no clear a...
To determine if some patients who tested positive for anti-Scl-70 antibody in clinical practice, but did not have classifiable systemic sclerosis, were negative for anti-Scl-70 antibody by the more sp...
Patients evaluated by a rheumatologist at a Scleroderma referral center who had tested positive for anti-Scl-70 antibody prior to referral, but did not have classifiable SSc based on clinical criteria...
52 patients were enrolled over an 8-year period, with 48 (92.3%) testing negative and 4 (7.7%) testing positive for anti-Scl-70 antibody by immunodiffusion. Of the 48 patients who tested negative, 18 ...
Assays for anti-Scl-70 antibody in commercial laboratories that are commonly utilized in clinical practice can produce false positive results. These results can lead to angst for patients, as well as ...
The Self-Efficacy to Manage Chronic Disease (SEMCD) scale is widely used, including in systemic sclerosis (SSc). The SEMCD has been validated in SSc, but the metric equivalence of the English and Fren...
Participants were adults from the Scleroderma Patient-Centered Intervention Network (SPIN) Cohort (N = 2159) who completed baseline measures in English (n = 1473) or French (n = 686) between May 2014 ...
Internal consistency reliability was high in English (α = .93, ω = .93) and French (α = .92, ω = .93). All correlations between the SEMCD and measures of health outcomes were moderate to large, statis...
Scores from English- and French-speaking adults with SSc can be combined for analysis or compared....
Localized scleroderma, also known as Morphea, is a chronic inflammatory condition of connective tissue, the etiology of which is unknown. There is skin thickening with increased quantities of collagen...
A 35-year-old lady with stable localized scleroderma had an atrophic scar on the right side of her face extending from the labio-mental crease to the midline of the chin. The contour of the chin was l...
Hyaluronic acid filler can be used safely in cases of stable localized scleroderma with facial atrophies. It is an effective, minimally invasive treatment with minimal downtime. It is extremely import...
Some individuals with systemic sclerosis (SSc) report positive mental health, despite severe disease manifestations, which may be associated with resilience, but no resilience measure has been validat...
Eligible participants were enrolled in the Scleroderma Patient-centered Intervention Network Cohort and completed the CD-RISC-10 between August 2022 and January 2023. We used confirmatory factor analy...
A total of 962 participants were included in this analysis. CFA supported a single-factor structure (Tucker-Lewis index = 0.99, comparative fit index = 0.99, root mean square error of approximation = ...
The CD-RISC-10 is a valid and reliable measure of resilience in SSc, with score comparability across English and French versions....
Loneliness has been associated with poorer health-related quality of life but has not been studied in patients with systemic sclerosis (SSc). The current study was undertaken to examine and compare th...
This study used baseline cross-sectional data from 775 adults enrolled in the Scleroderma Patient-Centered Intervention Network (SPIN) COVID-19 Cohort. Reliability and validity of ULS-6 scores overall...
CFA for the total sample supported the single-factor structure (comparative fit index [CFI] 0.96, standardized root mean residual [SRMR] 0.03), and all standardized factor loadings for items were larg...
Analyses demonstrated evidence of acceptable reliability and validity of ULS-6 scores in English- and French-speaking adults with SSc. DIF analysis supported use of the ULS-6 to examine comparative ex...
We investigated the impact of synthetic nucleic acid antigens on the autoantibody profiles in patients with localized scleroderma, an autoimmune skin disease. Anti-DNA antibodies, including double-str...
The updated S2k guideline deals with the diagnosis and therapy of localized scleroderma (LoS). LoS represents a spectrum of sclerotic skin diseases in which, depending on the subtype and localisation,...
More people with rare diseases likely receive disease education and emotional and practical support from peer-led support groups than any other way. Most rare-disease support groups are delivered outs...
The trial was a pragmatic, two-arm partially nested randomised controlled trial with 1:1 allocation into intervention or waitlist control. Eligible participants were existing or candidate peer support...
One hundred forty-eight participants were randomised to intervention (N = 74) or waitlist (N = 74). Primary outcome data were provided by 146 (99%) participants. Mean number of sessions attended was 1...
Peer support group leader education improved leader self-efficacy substantially. The program could be easily adapted for support group leaders in other rare diseases....
NCT03965780 ; registered on May 29, 2019....